Drugs / BF844
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06592131 | Sep 2024 → Mar 2025 overdue | Usher syndrome type 3 | EyeXCel Pty. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BF844 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06592131 ↗ |
| Modality | Small molecule | “BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.” NCT06592131 ↗ |
| Route | Oral | “of BF844 When Administered Orally to Healthy Adult Participants” NCT06592131 ↗ |